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Abstract

Natural killer cells are the main agents of innate immunity. Since 1970, various
studies have repeatedly confirmed their involvement in decreasing local tumor
growth and also decreasing the risk of metastasis, due to their cytotoxic effects and
also through the release of immunostimulatory cytokines such as IFN-gamma. In the
1990s, several studies demonstrated the existence of certain inhibiting and
stimulating receptors of these cells, leading to the concept of “induced self”, thus
explaining why tumors with MHC-1 are destroyed and autologous cells without it
are saved out. Recognition and destruction of tumor cells by the NK cells are the
result of complex interactions between inhibiting and activating factors. This paper,
based on extensive research of currently available studies, summarizes the
mechanisms employed by the NK cells to destroy the cancer cells, thus highlighting
their role in the risk of tumor recurrence as well as their use and handling in certain
types of immunotherapy.
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Introduction
In 1975, interest was raised by the identification of
certain cells with lymphocyte morphology, present in
both humans and mice, cells with the ability to destroy
modified cells without being previously activated (1).
The difference between B and T lymphocytes is
represented by the existence of a primary entity that does
not require activation (2).
Karre and colleagues introduced the “missing self”
hypothesis that basically stipulates that these cells have
the ability to detect and destroy cells with MHC-1
deficiency (major histocompatibility complex) (3). In the
1990s, several studies demonstrated the existence of
certain inhibiting and stimulating receptors of the NK
Figure 1. The High and Low-Cytokine Production
(schematic representation) (9).

cells, leading to the concept of “induced self”, thus
explaining why tumors with MHC-1 are destroyed and

Discussion

autologous cells without expression of MHC-1 are saved
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out (4).

Growth and tumor invasion are the result of

Consequently, these cells can identify and destroy a

wide range of abnormal cells (tumor cells, virally interactions between the tumor and the surrounding
infected cells, cells coupled with antibodies, cells under tissues, by initiating angiogenesis and the involvement
a certain degree of stress), preserving healthy “self” cells
(5). NK cells represent 5-20% of the mononuclear
peripheral blood cells, usually defined as CD16+, CD
56+, CD3- and are found in the liver, peritoneal cavity,
placenta and the uterine mucosa (6).
Depending on the density of CD16 and CD56

of

the

immune

system

(innate

and

acquired).

Clinicopathological signification of these processes is
given by the infiltration of the tumor with lymphocytes.
Lymphocytes T CD8+ and NK cells are representative
agents of the anti-tumoral immunity (10).
Some studies have shown a link between the number
of lymphocytes and survival in certain types of cancer,

present on the surface, NK cells can be divided into two

as the lower the number of NK liver cells the more
subpopulations: CD56 dim (moderate presence of CD56, advanced the neoplasm. These results suggest that the
predominantly displaying CD16 – and with high metastasis is due to ineffective antitumor liver
cytotoxic potential) and CD56 bright (CD16 presence mechanisms because of a low number of NK cells (11,
greatly reduced, reduced cytotoxicity but with high 12). Studies were extended in order to explain the
cytokine production after activation) (7). Recently, a decline in the number of the NK cells in advanced
new NK cell marker – NKp46- has been discovered in cancer stages, demonstrating that the tumor allegedly
humans and mice (8, 9).

inhibits the NK activating receptors and stimulates the
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inhibitory receptors, thus conducing to metastatic and less efficient. It needs the presence of TNF ligands
expansion (13).

on the cellular surface, ligands that will latch onto the

These results have defined the concept of the tumor Fas receptors on the surface of the target cells (19);
cell associated with the NK cell phenotype – NK

3. Through the activity of the IFN-gamma, the

humoral infiltrates (14-16). In certain cancers, not only activated NK cells secrete numerous cytokines (IFN-g,
NK cells present in the tumor may have different TNF-alpha, IL-10, IL-13 etc.). Among IFN effects, the
phenotypes or display a decrease in cytotoxicity but also following must be highlighted: inhibits cell proliferation
the NK cells in the peripheral blood may show the same in vitro and indirectly slows tumor growth in vivo by
changes (studies done on patients with metastatic stimulating

anti-angiogenic

factors;

increases

the

malignant melanoma have ascertained the reduction of sensitivity of tumor cells to the action of perforins and
NK cell activity and a reduction of IFN gamma apoptosis; elimination of sarcoma and metastasis
production as well as an increase in CD16 in the induced by methylcholanthrene (carcinogenic chemical
detriment of the CD56 bright). Although the molecular agent); stimulates the dendritic cells, by which it
mechanisms responsible for reducing receptor activity in indirectly contributes to tumor control, by means of Tperipheral blood are not yet known, the hypothesis is lymphocytes (20).
that the increase in the soluble serum values of tumor
receptors would inhibit the cell receptors, contributing to
a diminished NK cell activity. It is certain that the NK
cells have a tumor fighting potential but, taken in
consideration the results mentioned above, work must
continue towards fully understanding and activating this
potential (17).
 Mechanisms of action for natural killer cells
NK cells recognize target cells via receptors on the
cell surface, which can be inhibited or stimulated by
various conditions. For NK cells to be active, the

Figure 2. The schematic view of the mechanism of
action and innate killing of a NK cell (with permission
from http://nantkwest.com/platform/).

 The role of NK cells in limiting the tumor growth

receptors must be stimulated. Until now we know 3 and metastasis
The current advances in this field have established
types of NK cell action:
1. Throughout perforin-granzime system. Releasing some facts. Among them:
of these cytotoxic beads is the fastest and the most  It has been shown in mice that the tumor
effective mechanism for cell lysis. Trials made on cytotoxicity depends on the presence of cell surface
perforin-deficient mice have shown a reduced ability of ligands. There is little available information about the
tumor lysis, suggesting that perforins are indispensable mechanisms of NK cell migration in tumors, while it is
for NK cell cytotoxicity. Several studies have shown the established that selectins play a role in this process (21).
importance of perforins in tracking the cancer relapse  Mice with a low NK cell count have a higher
risk. The role of granzimes is not understood yet (18);

predisposition to chemical induced neoplasms, hence a

2. The induction of apoptosis is done by the TNF role of NK cells in tracking risk of developing
ligand family. This mechanism is slower (several hours) malignancies can be considered (22).
33
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 Experiments on animals have shown the ability of  Blocking the inhibitory receptors
NK cells to inhibit the development of lung metastasis
following treatment with IFN.

Blocking the inhibitors receptors Ly49 increases
tumor activity both in vivo and in vitro. Current

 An 11-year study on humans has shown an increased experiments test antibodies which block KIR (postrisk of developing malignancy in patients with low transplant of hematopoietic stem cells) (29).
activity of NK cells (for example, patients with  Vaccinating the tumor with dendritic cells is
hereditary colorectal adenocarcinoma and metastatic currently in the (early) experimental stage (30).
melanoma have an altered mechanism of perforins (23).

 Ongoing clinical studies on NK cells

 Following administration of tumor cells in mice, NK  Study of the Combined Therapy for Pancreatic
cells released IFN, which stimulated dendritic cells, Cancer (Fuda Cancer Hospital, Guangzhou). This study
promoting a strong anti-tumor response of lymphocytes focuses on finding the differences in behavior of
T CD8+ ( 24).

advanced pancreatic cancer patients that received both

 The involvement of NK cells in the anti-tumor irreversible electroporation (IRE) and immunotherapy of
management

nature killer (NK) cells versus patients that received only

Although we know the NK cells advantage over the immunotherapy of nature killer (NK) cells without
T lymphocyte cells in the anti-tumor fight, their irreversible electroporation (IRE). It is in progress since
therapeutic potential yet remains unexplored. Research 2016;
on the scientific mechanisms of enhancing or inhibiting  Intraperitoneal

Natural

Killer

Cells

and

NK cells as well as methods to make tumor cells INCB024360 for Recurrent Ovarian, Fallopian Tube,
receptive to the cytotoxic activity of the NK cells led to and Primary Peritoneal Cancer (Masonic Cancer Center,
the

development

of

numerous

genetic

and University of Minnesota, USA). This is a single center

pharmacological methods to increase NK cell activity:

phase I trial designed to determine the maximum

 Cytokine administration

tolerated dose (MTD) of the oral IDO inhibitor

The potential of the IL-2 to enhance NK cytotoxicity INCB024360 when administered as part of a larger
was observed in vitro. This finding led to conducting regimen of intraperitoneal (IP) delivery of haplo
clinical trials on patients with metastatic melanoma and identical donor NK cells and IL-2after a nonrenal carcinoma. Trials in primates have shown myeloablative cyclophosphamide/ fludarabine (Cy/Flu)
increased systemic toxicity of IL-2, so that Berger used preparative regimen for the treatment of recurrent
IL-15 with IL-2 like properties, considering appropriate ovarian, fallopian tube, and primary peritoneal cancer;
the intermittent administration of IL-15 (25).

 Natural

 Monoclonal antibody therapy

Chemotherapy to Treat Advanced Melanoma or Kidney

Killer

Cells

Plus

IL-2

Following

Administration of monoclonal antibodies to target Cancer (National Cancer Institute, USA)- This study
the tumor may induce rapid degranulation of NK cells determines

the

ability of

the

administration of

and cell lysis. The efficiency of the monoclonal autologous natural killer (NK) cells plus aldesleukin (ILantibodies

anti-CD20

(Rituximab),

anti-Her2 2) following a non-myeloablative lymph depleting

(Transtuzumab™), receptors for epidermal growth factor preparative regimen to mediate tumor regression in
(Cetuximab™) is due partially to the cytotoxicity of NK patients with metastatic melanoma or kidney cancer, to
cells antibody-addicted (26-28).

determine the rate of repopulation of the natural killer
34
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cells in treated patients and to find the overall toxicity of
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